Tenaya Therapeutics Stock Investor Sentiment

TNYA Stock  USD 0.70  0  0.14%   
About 63% of Tenaya Therapeutics' investor base is looking to short. The analysis of the overall investor sentiment regarding Tenaya Therapeutics suggests that many traders are alarmed. The current market sentiment, together with Tenaya Therapeutics' historical and current headlines, can help investors time the market. In addition, many technical investors use Tenaya Therapeutics stock news signals to limit their universe of possible portfolio assets.
  

Tenaya Therapeutics Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards Tenaya Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
3 days ago at news.google.com         
Tenaya Therapeutics Strong Financial Position and Promising Clinical Trial Results Justify Buy Ratin...
Google News at Macroaxis
few days ago at news.google.com         
Morgan Stanley Has Lowered Expectations for Tenaya Therapeutics Stock Price - Defense World
Google News at Macroaxis
six days ago at seekingalpha.com         
Tenaya Therapeutics GAAP EPS of -0.28 beats by 0.04
seekingalpha News
six days ago at thelincolnianonline.com         
Tenaya Therapeutics Posts Earnings Results, Beats Expectations By 0.04 EPS
news
six days ago at gurufocus.com         
Tenaya Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides ...
Gurufocus Stories at Macroaxis
six days ago at gurufocus.com         
Disposition of 47 shares by Ali Faraz of Tenaya Therapeutics at 0.5384 subject to Rule 16b-3
Gurufocus Stories at Macroaxis
over a week ago at news.google.com         
Tenaya therapeutics director David Goeddel buys 24.9 million in stock - Investing.com
Google News at Macroaxis
over a week ago at gurufocus.com         
JPMorgan Chase Co. Reduces Stake in Tenaya Therapeutics Inc.
Gurufocus Stories at Macroaxis
over a week ago at gurufocus.com         
Acquisition by Parschauer Karah Herdman of 29532 shares of Tenaya Therapeutics at 7.12 subject to Ru...
Gurufocus Stories at Macroaxis
over a week ago at www.macroaxis.com         
Acquisition by Goeddel David V of 17857142 shares of Tenaya Therapeutics at 0.7 subject to Rule 16b-...
Macroaxis News
over a week ago at gurufocus.com         
Tenaya Therapeutics Announces Pricing of Public Offering
Gurufocus Stories at Macroaxis
over a week ago at benzinga.com         
US Futures Tumble As Traders Await Trumps Congress Address Volatility Is Certainly Being Fed By Trum...
benzinga news
over a week ago at seekingalpha.com         
Tenaya Therapeutics intends to offer and sell units shares tumble
seekingalpha News
over a week ago at gurufocus.com         
Tenaya Therapeutics Announces Proposed Public Offering
Gurufocus Stories at Macroaxis
over two weeks ago at news.google.com         
H.C. Wainwright maintains buy rating on Tenaya Therapeutics stock - MSN
Google News at Macroaxis
Far too much social signal, news, headlines, and media speculation about Tenaya Therapeutics that are available to investors today. That information is available publicly through Tenaya media outlets and privately through word of mouth or via Tenaya internal channels. However, regardless of the origin, that massive amount of Tenaya data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Tenaya Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Tenaya Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Tenaya Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Tenaya Therapeutics alpha.

Tenaya Therapeutics Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
Disposition of 215000 shares by Tingley Whittemore of Tenaya Therapeutics at 5.22 subject to Rule 16b-3
01/24/2025
2
Acquisition by Burroughs Amy L. of 34000 shares of Tenaya Therapeutics at 2.04 subject to Rule 16b-3
01/28/2025
3
Disposition of 353271 shares by Ali Faraz of Tenaya Therapeutics at 5.64 subject to Rule 16b-3
02/06/2025
4
Insider Trading
02/07/2025
5
JPMorgan Chase Co. Acquires Significant Stake in Tenaya Therapeutics Inc.
02/10/2025
6
Disposition of 28125 shares by Chihiro Saito of Tenaya Therapeutics at 3.06 subject to Rule 16b-3
02/18/2025
7
Tenaya Therapeutics intends to offer and sell units shares tumble
03/03/2025
8
Acquisition by Goeddel David V of 17857142 shares of Tenaya Therapeutics at 0.7 subject to Rule 16b-3
03/05/2025
9
Tenaya therapeutics director David Goeddel buys 24.9 million in stock - Investing.com
03/07/2025
10
Tenaya Therapeutics Posts Earnings Results, Beats Expectations By 0.04 EPS
03/10/2025
11
Tenaya Therapeutics Strong Financial Position and Promising Clinical Trial Results Justify Buy Rating - TipRanks
03/14/2025

Complementary Tools for Tenaya Stock analysis

When running Tenaya Therapeutics' price analysis, check to measure Tenaya Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tenaya Therapeutics is operating at the current time. Most of Tenaya Therapeutics' value examination focuses on studying past and present price action to predict the probability of Tenaya Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tenaya Therapeutics' price. Additionally, you may evaluate how the addition of Tenaya Therapeutics to your portfolios can decrease your overall portfolio volatility.
USA ETFs
Find actively traded Exchange Traded Funds (ETF) in USA
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Top Crypto Exchanges
Search and analyze digital assets across top global cryptocurrency exchanges